A A A

 

Wichtige Publikationen seit dem 01.01.2007:

 

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML. Schütz C, Inselmann S, Sausslele S, Dietz CT, Mu Ller MC, Eigendorff E, Brendel CA, Metzelder SK, Bru Mmendorf TH, Waller C, Dengler J, Goebeler ME, Herbst R, Freunek G, Hanzel S, Illmer T, Wang Y, Lange T, Finkernagel F, Hehlmann R, Huber M, Neubauer A, Hochhaus A, Guilhot J, Xavier Mahon F, Pfirrmann M, Burchert A.
Leukemia. 2017 Apr;31(4):829-836.

 

PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation.  Albring JC, Inselmann S, Sauer T, Schliemann C, Altvater B, Kailayangiri S, Rössig C, Hartmann W, Knorrenschild JR, Sohlbach K, Groth C, Lohoff M, Neubauer A, Berdel WE, Burchert A, Stelljes M.
Bone Marrow Transplant.2017 Feb;52(2):317-320.

 

Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. Sopper S, Mustjoki S, White D, Hughes T, Valent P, Burchert A, Gjertsen BT, Gastl G, Baldauf M, Trajanoski Z, Giles F, Hochhaus A, Ernst T, Schenk T, Janssen JJ, Ossenkoppele GJ, Porkka K, Wolf D.
J Clin Oncol. 2017 Jan 10;35(2):175-184.

 

[Molecular tumour therapy]. Michel C, Neubauer A, Burchert A.
Internist (Berl). 2015 Dec;56(12):1389-400; quiz 1401-2.

 

Study Alliance Leukaemia.. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U, Baldus CD,  Brandts CH, Kunzmann V, Einsele H, Krämer A, Schäfer-Eckart K, Neubauer A, Burchert A, Giagounidis A, Krause SW, Mackensen A, Aulitzky W, Herbst R, Hänel M, Kiani A, Frickhofen N, Kullmer J, Kaiser U, Link H, Geer T, Reichle A, Junghanß C, Repp R, Heits F, Dürk H, Hase J, Klut IM, Illmer T, Bornhäuser M, Schaich M, Parmentier S, Görner M, Thiede C, von Bonin M, Schetelig J, Kramer M, Berdel WE,  Ehninger G.
Lancet Oncol. 2015 Dec;16(16):1691-9.

 

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N.
Leukemia. 2015 Oct;29(10):2062-8.

 

Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung and the German CML Study Group.. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML study IV. Saussele S, Krauss MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, Hanfstein B, Fabarius A, Kraemer D, Berdel WE, Bentz M, Staib P, de Wit M, Wernli M, Zettl F, Hebart HF, Hahn M, Heymanns J, Schmidt-Wolf I, Schmitz N, Eckart MJ, Gassmann W, Bartholomäus A, Pezzutto A, Leibundgut EO, Heim D, Krause SW, Burchert A, Hofmann WK, Hasford J, Hochhaus A, Pfirrmann M, Müller MC.
Blood. 2015 Jul 2;126(1):42-9.

 

NFATc1 as a therapeutic target in FLT3-ITD-positive AML. Metzelder SK, Michel C, von Bonin M, Rehberger M, Hessmann E, Inselmann S, Solovey M, Wang Y, Sohlbach K, Brendel C, Stiewe T, Charles J, Ten Haaf A, Ellenrieder V, Neubauer A, Gattenlöhner S, Bornhäuser M, Burchert A.
Leukemia. 2015 Jul;29(7):1470-7.

 

Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia. Burchert A, Saussele S, Eigendorff E, Müller MC, Sohlbach K, Inselmann S, Schütz C, Metzelder SK, Ziermann J, Kostrewa P, Hoffmann J, Hehlmann R, Neubauer A, Hochhaus A.
Leukemia. 2015 Jun;29(6):1331-5.

 

Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistence. Burchert A.
Curr Hematol Malig Rep. 2014 Mar;9(1):9-16.

 

High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.Metzelder SK, Schroeder T, Finck A, Scholl S, Fey M, Götze K, Linn YC, Kröger M, Reiter A, Salih HR, Heinicke T, Stuhlmann R, Müller L, Giagounidis A, Meyer RG, Brugger W, Vöhringer M, Dreger P, Mori M, Basara N, Schäfer-Eckart K, Schultheis B, Baldus C, Neubauer A, Burchert A.
Leukemia. 2012 Nov;26(11):2353-9.

 

Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic  myeloid leukemia under imatinib.Kumari A, Brendel C, Hochhaus A, Neubauer A, Burchert A.
Blood. 2012 Jan 12;119(2):530-9.

 

[Chronic myeloid leukemia. Diagnostics, therapy and future strategy]. Burchert A, Neubauer A.  
Internist (Berl). 2011 Mar;52(3):283-93; quiz 294-5.

 

[Sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia: a novel treatment option].Metzelder SK, Wollmer E, Neubauer A, Burchert A.
Dtsch Med Wochenschr. 2010 Sep;135(38):1852-6.

 

Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. Burchert A, Müller MC, Kostrewa P, Erben P, Bostel T, Liebler S, Hehlmann R, Neubauer A, Hochhaus A.
J Clin Oncol. 2010 Mar 10;28(8):1429-35.

 

Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Metzelder S, Wang Y, Wollmer E, Wanzel M, Teichler S, Chaturvedi A, Eilers M, Enghofer E, Neubauer A, Burchert A.
Blood. 2009 Jun 25;113(26):6567-71.

 

Roots of imatinib resistance: a question of self-renewal?  Burchert A.
Drug Resist Updat. 2007 Aug-Oct;10(4-5):152-61.

 

Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation. Wang Y, Cai D, Brendel C, Barett C, Erben P, Manley PW, Hochhaus A, Neubauer A, Burchert A.
Blood. 2007 Mar 1;109(5):2147-55.